文献速递脊柱关节炎

银屑病关节炎患者启用生物制剂或阿普米司特的主要不良心血管事件风险:全国性队列研究

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该全国性队列研究基于法国医保数据库,纳入2015–2019年新启用生物DMARD或阿普米司特的成人PsA患者,排除既往心血管病者。主要终点为主要不良心血管事件(MACE)。经倾向评分加权后,IL-12/23与IL-17抑制剂较TNF抑制剂显著增加MACE风险,阿普米司特无显著增加。

要点

  • PsA新启用IL-12/23或IL-17抑制剂者MACE风险约为TNF抑制剂的2倍。
  • 阿普米司特较TNF抑制剂MACE风险无显著升高(加权HR 1.3,95%CI 0.8–2.2)。

核心结论

  • 在PsA新用药者中,IL-12/23和IL-17抑制剂较TNF抑制剂与更高的MACE风险相关,阿普米司特无显著增加。

研究设计与样本

  • 全国性队列研究,使用法国医保行政数据库链接医院出院数据库,纳入2015–2019年新启用bDMARD或阿普米司特的成人PsA患者,排除既往心血管病者,随访至2019年12月31日。
  • 共纳入9510例bDMARD新用户(平均年龄48.5岁,s.d. 12.7;42%男性)和1885例阿普米司特新用户(平均年龄54.0岁,s.d. 12.5;44%男性)。
  • bDMARD新用户中,7289例起始TNF抑制剂,1058例起始IL-12/23抑制剂,1163例起始IL-17抑制剂。
  • 采用倾向评分加权Cox模型和Fine-Gray模型进行时间至事件分析。

主要发现

  • MACE发生于51例(0.4%)患者。
  • 倾向评分加权后,IL-12/23抑制剂较TNF抑制剂的加权风险比(HR)为2.0(95%CI 1.3–3.0)。
  • IL-17抑制剂较TNF抑制剂的加权HR为1.9(95%CI 1.2–3.0)。
  • 阿普米司特较TNF抑制剂的加权HR为1.3(95%CI 0.8–2.2),无显著增加。
  • Fine-Gray竞争风险模型结果相似。

关键数值与推荐

  • 主要终点为MACE发生,采用倾向评分加权Cox和Fine-Gray模型分析。
  • IL-12/23抑制剂对比TNF抑制剂的加权HR 2.0(95%CI 1.3–3.0)。
  • IL-17抑制剂对比TNF抑制剂的加权HR 1.9(95%CI 1.2–3.0)。
  • 阿普米司特对比TNF抑制剂的加权HR 1.3(95%CI 0.8–2.2)。

临床怎么用

  • 对PsA患者选择bDMARD时,应结合心血管风险考虑:IL-12/23或IL-17抑制剂较TNF抑制剂可能增加MACE风险。
  • 阿普米司特在心血管安全性方面未显示较TNF抑制剂显著增加风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Several biological DMARDs (bDMARDs) have demonstrated anti-inflammatory effects in PsA. However, their comparative cardiovascular safety profiles remain unknown. We evaluated the risk of major adverse cardiovascular events (MACEs) in PsA patients on therapy with different classes of bDMARDs and apremilast. METHODS: This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. All adults with PsA who were new users of bDMARDs/apremilast (neither in the year before the index date) during 2015-19 were included. Patients with previous cardiovascular diseases were excluded. End of follow-up was 31 December 2019. The primary endpoint was an occurrence of MACEs in a time-to-event analysis with propensity score-weighted Cox and Fine-Gray models. RESULTS: Between 2015 and 2019, we included 9510 bDMARD new users [mean age 48.5 (s.d. 12.7) years; 42% men], including 7289 starting a TNF inhibitor, 1058 an IL-12/23 inhibitor and 1163 an IL-17 inhibitor, with 1885 apremilast new users [mean age 54.0 (s.d. 12.5) years; 44% men]. MACEs occurred in 51 (0.4%) patients. After propensity score weighting, the risk of MACEs was significantly greater with IL-12/23 (weighted hazard ratio 2.0, 95% CI 1.3, 3.0) and IL-17 (weighted hazard ratio 1.9, 95% CI 1.2, 3.0) inhibitors than TNF inhibitors, with no significant increased risk with apremilast (weighted hazard ratio 1.3, 95% CI 0.8, 2.2). Similar results were observed with the Fine-Gray competing risks survival model. CONCLUSION: Analysis of a large database revealed a small overall number of MACEs, and the risk of MACEs was greater for PsA new users of IL-12/23 and IL-17 vs TNF inhibitors.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pina Vegas L, Le Corvoisier P, Penso L, et al. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022. PMID: 34244706. doi:10.1093/rheumatology/keab522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。